Solid Q3 with 7% organic growth and 8% EBITDA beat vs. ABGSC. Unchanged guidance leaves a wide Q4 range and question marks. 6-9% negative EPS revisions, narrowing FVR to DKK 26-40.
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Solid Q3 with 7% organic growth and 8% EBITDA beat vs. ABGSC. Unchanged guidance leaves a wide Q4 range and question marks. 6-9% negative EPS revisions, narrowing FVR to DKK 26-40.
